Skip to content
2000
Volume 26, Issue 1
  • ISSN: 1871-5249
  • E-ISSN: 1875-6166

Abstract

Background

The pharmacophoric approach relies on the theory of possessing ubiquitous chemical functionalities, and carrying a uniform spatial conformation that provides a route to enhanced potency on the same target receptor. JNK3, also known as c-Jun N-terminal kinase 3, is a protein kinase that plays a crucial role in various cellular processes, particularly in the central nervous system (CNS). In this study, a kernel-based partial least square (KPLS)-based Two-dimensional Quantitative structural activity relationship (2D QSAR) model to predict pharmacophores responsible for c-Jun-N-terminal kinase 3 (JNK3) inhibition.

Methods

A library of small molecule JNK3 inhibitors was created from the literature, and a predictive model was built using Canvas 2.6.

Results

The analysis revealed key structural determinants of activity. Compounds with high pIC values (>6) showed numerous favorable contributions, particularly secondary benzamide nitrogen and methylene groups. Steric effects were more influential than inductive effects, with bulkier groups like t-butyl reducing activity. Positive contributions were observed with OH, O-CH3, and -F substituents, while unfavorable effects were linked to tertiary nitrogen, methyl, and primary amino groups. Substituted sulphonamides and benzotriazole moieties enhanced activity unless modified with amino or carbonyl groups. Favorable contributions were noted for terminal heterocyclic rings like pyrimidinyl acetonitrile, whereas phenyl substitutions and certain piperazine configurations were detrimental. Hydrogen in the urea moiety and avoiding bulky substitutions were crucial for activity. These insights guide the design of potent JNK3 inhibitors.

Conclusion

The present study highlights the significant impact of substituents on molecular activity, with steric effects, particularly on the phenyl ring, playing a dominant role. Favorable contributions are linked to substitutions like hydroxyl, methoxy, and fluorine, while bulky and meta substitutions reduce activity. Functional groups like unsubstituted sulfonamide or free hydrogen in urea are crucial for activity. Insights into steric, electronic, and positional factors, combined with analysis of JNK3 inhibitors, will guide the design of more selective molecules.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnsamc/10.2174/0118715249345667250216034023
2026-02-01
2026-03-02

  • From This Site

    /content/journals/cnsamc/10.2174/0118715249345667250216034023
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. PkN. RajanR.K. NanchappanV. KaruppaiahA. ChandrasekaranJ. JayaramanS. GunasekaranV. C-Glucosyl Xanthone derivative Mangiferin downregulates the JNK3 mediated caspase activation in Almal induced neurotoxicity in differentiated SHSY-5Y neuroblastoma cells.Toxicol. Mech. Methods202333970771810.1080/15376516.2023.2237106 37455591
     [Google Scholar]
  2. RajanR.K. KumarR.P. RamanathanM. Piceatannol improved cerebral blood flow and attenuated JNK3 and mitochondrial apoptotic pathway in a global ischemic model to produce neuroprotection.Naunyn Schmiedebergs Arch. Pharmacol.2024397147949610.1007/s00210‑023‑02616‑0 37470802
     [Google Scholar]
  3. RajanR.K. RamanathanM. Piceatannol selectively inhibited the JNK3 enzyme and augmented apoptosis through inhibition of Bcl‐2/Cyt‐c/caspase‐dependent pathways in the oxygen-glucose deprived SHSY‐5Y cell lines: In silico and in vitro study.Chem. Biol. Drug Des.20241032e1445810.1111/cbdd.14458 38383061
     [Google Scholar]
  4. MusiC.A. AgròG. SantarellaF. IervasiE. BorselloT. JNK3 as therapeutic target and biomarker in neurodegenerative and neurodevelopmental brain diseases.Cells2020910219010.3390/cells9102190 32998477
     [Google Scholar]
  5. BusquetsO. Espinosa-JiménezT. EttchetoM. OlloquequiJ. BullóM. CarroE. CanteroJ.L. CasadesúsG. FolchJ. VerdaguerE. AuladellC. CaminsA. JNK1 and JNK3: Divergent functions in hippocampal metabolic-cognitive function.Mol. Med.20222814810.1186/s10020‑022‑00471‑y 35508978
     [Google Scholar]
  6. WuY. ZhaoY. GuanZ. JNK3 inhibitors as promising pharmaceuticals with neuroprotective properties.Cell Adh. Migr.202418111110.1080/19336918.2024.2316576
     [Google Scholar]
  7. JunJ. BaekJ. YangS. MoonH. KimH. ChoH. HahJ.M. Discovery of a potent and selective JNK3 inhibitor with neuroprotective effect against amyloid β-induced neurotoxicity in primary rat neurons.Int. J. Mol. Sci.202122201108410.3390/ijms222011084 34681742
     [Google Scholar]
  8. WuQ. WuW. JacevicV. Selective inhibitors for JNK signalling: A potential targeted therapy in cancer.J. Enzyme Inhib. Med. Chem.202035157458310.1080/14756366.2020.1720013
     [Google Scholar]
  9. YaoC. ShenZ. ShenL. KadierK. ZhaoJ. GuoY. XuL. CaoJ. DongX. YangB. Identification of Potential JNK3 Inhibitors: A Combined Approach Using Molecular Docking and Deep Learning-Based Virtual Screening.Pharmaceuticals20231610145910.3390/ph16101459 37895928
     [Google Scholar]
  10. DuongM.T.H. AhnH.C. Fragment-based and structural investigation for discovery of JNK3 inhibitors.Pharmaceutics2022149190010.3390/pharmaceutics14091900 36145648
     [Google Scholar]
  11. QinP. RanY. LiuY. WeiC. LuanX. NiuH. PengJ. SunJ. WuJ. Recent advances of small molecule JNK3 inhibitors for Alzheimer’s disease.Bioorg. Chem.202212810609010.1016/j.bioorg.2022.106090 35964505
     [Google Scholar]
  12. PaiA. Fingerprint based two-dimensional qsar studies on pyrazolo quinazolines as Cdk2 inhibitors: A rational approach for the design of novel anticancer agents.Indian J. Pharm. Educ. Res.2019533ss299s31210.5530/ijper.53.3s.100
     [Google Scholar]
  13. BastikarV. BastikarA. GuptaP. Quantitative structure-activity relationship-based computational approaches. Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV-2 InfectionAcademic Press202219120510.1016/B978‑0‑323‑91172‑6.00001‑7
     [Google Scholar]
  14. NevesB.J. BragaR.C. Melo-FilhoC.C. Moreira-FilhoJ.T. MuratovE.N. AndradeC.H. QSAR-based virtual screening: Advances and applications in drug discovery.Front. Pharmacol.20189127510.3389/fphar.2018.01275 30524275
     [Google Scholar]
  15. FalchiF. BertozziS.M. OttonelloG. RudaG.F. ColombanoG. FiorelliC. MartucciC. BertorelliR. ScarpelliR. CavalliA. BandieraT. ArmirottiA. Kernel-based, partial least squares quantitative structure-retention relationship model for UPLC retention time prediction: A useful tool for metabolite identification.Anal. Chem.201688199510951710.1021/acs.analchem.6b02075 27583774
     [Google Scholar]
  16. DeokarH. DeokarM. BuolamwiniJ.K. Integration of fingerprint-based similarity searching and kernel-based partial least squares analysis to predict inhibitory activity against CSK, HER2, JAK1, JAK2, and JAK3.Mol. Divers.202310.1007/s11030‑022‑10596‑1 36648693
     [Google Scholar]
  17. Minh QuangN. Tran ThaiH. Le ThiH. Duc CuongN. HienN.Q. HoangD. NgocV.T.B. Ky MinhV. Van TatP. Novel thiosemicarbazone quantum dots in the treatment of Alzheimer’s disease combining in silico models using fingerprints and physicochemical descriptors.ACS Omega2023812110761109910.1021/acsomega.2c07934 37008140
     [Google Scholar]
  18. BaiY. JianX. LongY. 2006.Kernel partial least-squares regression.The 2006 IEEE International Joint Conference on Neural Network Proceedings Vancouver, BC, Canada, 16-21 July 2006, pp. 1231-1238.
     [Google Scholar]
  19. Mello-RománJ.D. HernandezA. KPLS optimization approach using genetic algorithms.Procedia Comput. Sci.20201701153116010.1016/j.procs.2020.03.051
     [Google Scholar]
  20. Bouakouk-ChittiZ. FeddalS. MeyarM. Kellou-TairiS. Ligand-based studies on cis-stilbene derivatives as cyclo-oxygenase inhibitors.Med. Chem. Res.20172681801181110.1007/s00044‑017‑1890‑1
     [Google Scholar]
  21. SwahnB.M. HuertaF. KallinE. MalmströmJ. WeigeltT. ViklundJ. WomackP. XueY. ÖhbergL. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.Bioorg. Med. Chem. Lett.200515225095509910.1016/j.bmcl.2005.06.083 16140012
     [Google Scholar]
  22. SwahnB.M. XueY. ArzelE. KallinE. MagnusA. PlobeckN. ViklundJ. Design and synthesis of 2′-anilino-4,4′-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3.Bioorg. Med. Chem. Lett.20061651397140110.1016/j.bmcl.2005.11.039 16337120
     [Google Scholar]
  23. CaoJ. GaoH. BemisG. SalituroF. LedeboerM. HarringtonE. WilkeS. TaslimiP. PazhanisamyS. XieX. JacobsM. GreenJ. Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors.Bioorg. Med. Chem. Lett.200919102891289510.1016/j.bmcl.2009.03.043 19361991
     [Google Scholar]
  24. ShinY. ChenW. HabelJ. DuckettD. LingY.Y. KoenigM. HeY. VojkovskyT. LoGrassoP. KameneckaT.M. Synthesis and SAR of piperazine amides as novel c-jun N-terminal kinase (JNK) inhibitors.Bioorg. Med. Chem. Lett.200919123344334710.1016/j.bmcl.2009.03.086 19433357
     [Google Scholar]
  25. SongX. ChenW. LinL. RuizC.H. CameronM.D. DuckettD.R. KameneckaT.M. Synthesis and SAR of 2-Phenoxypyridines as novel c-Jun N-terminal kinase inhibitors.Bioorg. Med. Chem. Lett.201121237072707510.1016/j.bmcl.2011.09.090 22004719
     [Google Scholar]
  26. ZhengK. IqbalS. HernandezP. ParkH. LoGrassoP.V. FengY. Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives.J. Med. Chem.20145723100131003010.1021/jm501256y 25393557
     [Google Scholar]
  27. HeY. DuckettD. ChenW. LingY.Y. CameronM.D. LinL. RuizC.H. LoGrassoP.V. KameneckaT.M. KoenigM. Synthesis and SAR of novel isoxazoles as potent c-jun N-terminal kinase (JNK) inhibitors.Bioorg. Med. Chem. Lett.201424116116410.1016/j.bmcl.2013.11.052 24332487
     [Google Scholar]
  28. JungH. AmanW. HahJ.M. Novel scaffold evolution through combinatorial 3D-QSAR model studies of two types of JNK3 inhibitors.Bioorg. Med. Chem. Lett.201727102139214310.1016/j.bmcl.2017.03.063 28372912
     [Google Scholar]
  29. RückleT. BiamonteM. Grippi-VallottonT. ArkinstallS. CambetY. CampsM. ChabertC. ChurchD.J. HalazyS. JiangX. MartinouI. NicholsA. SauerW. GottelandJ.P. Design, synthesis, and biological activity of novel, potent, and selective (benzoylaminomethyl)thiophene sulfonamide inhibitors of c-Jun-N-terminal kinase.J. Med. Chem.200447276921693410.1021/jm031112e 15615541
     [Google Scholar]
  30. GaillardP. Jeanclaude-EtterI. ArdissoneV. ArkinstallS. CambetY. CampsM. ChabertC. ChurchD. CirilloR. GretenerD. HalazyS. NicholsA. SzyndralewiezC. VitteP.A. GottelandJ.P. Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.J. Med. Chem.200548144596460710.1021/jm0310986 15999997
     [Google Scholar]
  31. ZhengK. ParkC.M. IqbalS. HernandezP. ParkH. LoGrassoP.V. FengY. Pyridopyrimidinone derivatives as potent and selective c-Jun N-terminal kinase (JNK) inhibitors.ACS Med. Chem. Lett.20156441341810.1021/ml500474d 25893042
     [Google Scholar]
  32. RajanR.K. RamanathanM. Identification and neuroprotective evaluation of a potential c-Jun N-terminal kinase 3 inhibitor through structure-based virtual screening and in-vitro assay.J. Comput. Aided Mol. Des.202034667168210.1007/s10822‑020‑00297‑y 32040807
     [Google Scholar]
  33. DuanJ. DixonS.L. LowrieJ.F. ShermanW. Analysis and comparison of 2D fingerprints: Insights into database screening performance using eight fingerprint methods.J. Mol. Graph. Model.201029215717010.1016/j.jmgm.2010.05.008 20579912
     [Google Scholar]
  34. HoffelnerB.S. AndreevS. PlankN. KochP. Photocaging of pyridinylimidazole-based covalent JNK3 inhibitors affords spatiotemporal control of the binding affinity in live cells.Pharmaceuticals202316226410.3390/ph16020264 37259409
     [Google Scholar]
  35. KulkarniS.A. MadhavanT. Hologram quantitative structure activity relationship analysis of JNK antagonists.J. Chosun Nat. Sci.201582818810.13160/ricns.2015.8.2.81
     [Google Scholar]
  36. ZhangT. Inesta-VaqueraF. NiepelM. ZhangJ. FicarroS.B. MachleidtT. XieT. MartoJ.A. KimN. SimT. LaughlinJ.D. ParkH. LoGrassoP.V. PatricelliM. NomanbhoyT.K. SorgerP.K. AlessiD.R. GrayN.S. Discovery of potent and selective covalent inhibitors of JNK.Chem. Biol.201219114015410.1016/j.chembiol.2011.11.010 22284361
     [Google Scholar]
  37. Abu RabahR.R. SebastianA. VunnamS. SultanS. TaraziH. AnbarH.S. ShehataM.K. ZaraeiS.O. ElgendyS.M. Al ShammaS.A. OmarH.A. Al-TelT.H. El-GamalM.I. Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.Bioorg. Med. Chem.20226911689410.1016/j.bmc.2022.116894 35764033
     [Google Scholar]
  38. VaasS. ZimmermannM.O. SchollmeyerD. StahleckerJ. EngelhardtM.U. RheinganzJ. DrotleffB. OlfertM. LämmerhoferM. KramerM. StehleT. BoecklerF.M. Principles and applications of CF 2 X moieties as unconventional halogen bond donors in medicinal chemistry, chemical biology, and drug discovery.J. Med. Chem.20236615102021022510.1021/acs.jmedchem.3c00634 37487500
     [Google Scholar]
  39. TandonN. LuxamiV. KantD. TandonR. PaulK. Current progress, challenges and future prospects of indazoles as protein kinase inhibitors for the treatment of cancer.RSC Advances20211141252282525710.1039/D1RA03979B 35478899
     [Google Scholar]
  40. El-GamalM.I. ZaraeiS.O. MadkourM.M. AnbarH.S. Evaluation of substituted pyrazole-based kinase inhibitors in one decade (2011-2020): Current status and future prospects.Molecules202227133010.3390/molecules27010330 35011562
     [Google Scholar]
  41. DuongM.T.H. LeeJ.H. AhnH.C. C-Jun N-terminal kinase inhibitors: Structural insight into kinase-inhibitor complexes.Comput. Struct. Biotechnol. J.2020181440145710.1016/j.csbj.2020.06.013 32637042
     [Google Scholar]
  42. CarboniS. HiverA. SzyndralewiezC. GaillardP. GottelandJ.P. VitteP.A. AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): A c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties.J. Pharmacol. Exp. Ther.20043101253210.1124/jpet.103.064246 14988419
     [Google Scholar]
  43. KameneckaT. JiangR. SongX. DuckettD. ChenW. LingY.Y. HabelJ. LaughlinJ.D. ChambersJ. Figuera-LosadaM. CameronM.D. LinL. RuizC.H. LoGrassoP.V. Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors.J. Med. Chem.201053141943110.1021/jm901351f 19947601
     [Google Scholar]
  44. NoëlR. ShinY. SongX. HeY. KoenigM. ChenW. LingY.Y. LinL. RuizC.H. LoGrassoP. CameronM.D. DuckettD.R. KameneckaT.M. Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-jun N-terminal kinase inhibitors.Bioorg. Med. Chem. Lett.20112192732273510.1016/j.bmcl.2010.11.104 21185177
     [Google Scholar]
  45. HomR.K. BowersS. SealyJ.M. TruongA.P. ProbstG.D. NeitzelM.L. NeitzR.J. FangL. BrogleyL. WuJ. KonradiA.W. ShamH.L. TóthG. PanH. YaoN. ArtisD.R. QuinnK. SauerJ.M. PowellK. RenZ. BardF. YednockT.A. Griswold-PrennerI. Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK.Bioorg. Med. Chem. Lett.201020247303730710.1016/j.bmcl.2010.10.066 21071223
     [Google Scholar]
  46. AnsideriF. MacedoJ.T. EitelM. El-GokhaA. ZinadD.S. ScarpelliniC. KudoloM. SchollmeyerD. BoecklerF.M. BlaumB.S. LauferS.A. KochP. Structural optimization of a pyridinylimidazole scaffold: Shifting the selectivity from p38α mitogen-activated protein kinase to c-Jun N-terminal kinase 3.ACS Omega2018377809783110.1021/acsomega.8b00668 30087925
     [Google Scholar]
  47. CrawfordT.D. NdubakuC.O. ChenH. BoggsJ.W. BravoB.J. DeLaTorreK. GiannettiA.M. GouldS.E. HarrisS.F. MagnusonS.R. McNamaraE. MurrayL.J. NonomiyaJ. SambroneA. SchmidtS. SmyczekT. StanleyM. VitorinoP. WangL. WestK. WuP. YeW. Discovery of selective 4-Amino-pyridopyrimidine inhibitors of MAP4K4 using fragment-based lead identification and optimization.J. Med. Chem.20145783484349310.1021/jm500155b 24673130
     [Google Scholar]
  48. TantawyE.S. NafieM.S. MorsyH.A. El-SayedH.A. MoustafaA.H. MohammedS.M. Synthesis of novel bioactive pyrido[2,3- d]pyrimidine derivatives with potent cytotoxicity through apoptosis as PIM-1 kinase inhibitors.RSC Advances20241416110981111110.1039/D4RA00902A 38586446
     [Google Scholar]
/content/journals/cnsamc/10.2174/0118715249345667250216034023
Loading
Identification of Pharmacophore Responsible for the JNK3 Enzyme Inhibition using KPLS-based QSAR Analysis
Central Nervous System Agents in Medicinal Chemistry 26, 63 (2026); https://doi.org/10.2174/0118715249345667250216034023
/content/journals/cnsamc/10.2174/0118715249345667250216034023
/content/journals/cnsamc/10.2174/0118715249345667250216034023
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): canvas 2.6; IC50; JNK3; KPLS; pharmacophore; QSAR

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test